CN1456348A - Chinese medicinal preparation for improving kidney fibrosis and its production - Google Patents
Chinese medicinal preparation for improving kidney fibrosis and its production Download PDFInfo
- Publication number
- CN1456348A CN1456348A CN 03129035 CN03129035A CN1456348A CN 1456348 A CN1456348 A CN 1456348A CN 03129035 CN03129035 CN 03129035 CN 03129035 A CN03129035 A CN 03129035A CN 1456348 A CN1456348 A CN 1456348A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- renal fibrosis
- salviae miltiorrhizae
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A Chinese medicine for relaxing the renal fibrosis is prepared from 6 Chinese-medicinal materials including peach kernel, red sage root, gynostemma pentaphyllum, etc. Its preparing process is also disclosed.
Description
Technical field:
The invention belongs to the Chinese medicine preparation technical field.Be specifically related to a kind of Chinese medicine preparation and preparation method of improving renal fibrosis.
Background technology:
Renal fibrosis indicates that kidney disease proceeds to end-stage renal failure, and its pathological characters is hyperplasia and the deposition of connective tissue at positions such as renal tubules stromas, thereby causes the normal kidney tissue structural deterioration, renal dysfunction and forfeiture.The inflammatory disorders of matter all can develop into renal fibrosis between glomerule, blood vessel, tubule, and renal fibrosis is the disease pathological change of serious harm human health.Therefore prevent and treat the treatment of renal fibrosis, and prevent that chronic renal failure is all significant for chronic nephropathy.
Heavy metal, Environmental Chemistry material, medicine etc. are to cause kidney poisoning and Fibrotic common cause.For the control of renal fibrosis, western medicine and medical practitioners does not still have special effective ways at present, is to treat the secondary risk factor that protopathy, control hyperglycemia hypertension etc. may cause renal failure mostly.According to research reports, Chinese medicine has certain anti-renal fibrosis effect, single medicinal material has Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Notoginseng, Cordyceps etc., and compound preparation has slow kidney health (Radix Astragali, Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae etc.), kidney tonifying blood fat reducing soup (Radix Astragali, Cordyceps, Herb Gynostemmae Pentaphylli general glycoside, Radix Puerariae), astragalus angelica mixture (Radix Astragali, Radix Angelicae Sinensis) etc.But these reports are in experimentation and clinical observation stage, still do not have the clinical new drug of treatment renal fibrosis.
Supporting vital QI and dispersing blood stasis side is made up of Radix Salviae Miltiorrhizae, Semen Persicae, Cordyceps mycelium etc., good effect of anti hepatic fibrosis is arranged, State Drug Administration's approval in 2002 is by this side's capsule preparations, and Chinese patent is 99113887.2, and denomination of invention is " a kind of medicine and preparation method for the treatment of chronic hepatopathy.Promptly " FUZHENG HUAYU JIAONANG " for listing new drug (traditional Chinese medicines card word Z20020053), is used for hepatitis B and hepatic fibrosis and belongs to " obstruction of collaterals by blood stasis, deficiency of the liver and kindey " card person.But useless between renal tubules the observation report of kidney disease such as matter inflammation and renal fibrosis thereof.Do not have to adopt the above compound preparation of identical 3 flavor medicines with supporting vital QI and dispersing blood stasis side yet, comprise capsule, tablet or electuary etc., be used for the report of renal fibrosis control.
Summary of the invention:
Technical problem to be solved by this invention is to study the drug effect of above-mentioned Chinese medicine " FUZHENG HUAYU JIAONANG ", further develops it and improves application in the Chinese medicine preparation of renal fibrosis in preparation.
The invention provides a kind of Chinese medicine preparation that improves renal fibrosis, the prescription of said preparation form with Chinese patent 99113887.2 in identical, the component that comprises the following weight proportioning is made per 1000 capsules and included: Semen Persicae 50-250, Radix Salviae Miltiorrhizae 300-700, Herb Gynostemmae Pentaphylli 200-600, fermented Cordyceps powder 150-450, Pollen Pini 50-250, Fructus Schisandrae Chinensis 50-250, starch are an amount of.
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Semen Persicae 100-200, Radix Salviae Miltiorrhizae 500-600, Herb Gynostemmae Pentaphylli 300-500, fermented Cordyceps powder 200-300, Pollen Pini 100-200, Fructus Schisandrae Chinensis 100-200, starch are an amount of.
The optimum weight of medicine of the present invention (part) proportioning is:
Semen Persicae 130, Radix Salviae Miltiorrhizae 530, Herb Gynostemmae Pentaphylli 400, fermented Cordyceps powder 260, Pollen Pini 130, Fructus Schisandrae Chinensis 130, starch are an amount of.
The production method that above-mentioned each component is made medicament capsule preparation of the present invention is:
Take by weighing Radix Salviae Miltiorrhizae, Semen Persicae, Herb Gynostemmae Pentaphylli and decoct with water, collecting decoction is got supernatant, is condensed into extractum, and cooling adds ethanol, and precipitation filters; Other takes by weighing fermented Cordyceps powder, and Fructus Schisandrae Chinensis adds alcohol heat reflux, and cooling merges ethanol liquid, filters the filtrate concentrate drying; Other takes by weighing Pollen Pini and adds the ethanol warm macerating, merges leachate, and concentrate drying becomes dried cream, gets above-mentioned three kinds of dried cream, mixes and pulverizes, and it is an amount of to add starch, mixing, and the fill capsule, promptly.
Preparation of the present invention is studied through pharmacological effect, has the new purposes that can improve renal fibrosis, and its result of the test is as follows:
A. pharmacological model: adopt the feedstuff that contains mercuric chloride, in oral 8 weeks of nursing rat, induce the kidney of rats interstitial fibrosis.
B. drug action: supporting vital QI and dispersing blood stasis side obviously improves the renal function of kidney region fibrosis rat, reduces serum urea nitrogen and creatinine.Significantly alleviate rat model nephridial tissue collagen (hydroxyproline) content, and significantly improve active and reduction malonaldehyde (MDA) content of rat model nephridial tissue superoxide dismutase (SOD), have good anti-nephridial tissue lipid peroxidation.Table 1.
Table 1 supporting vital QI and dispersing blood stasis side is to the influence of heavy metal poisoning rat blood serum renal function, nephridial tissue collagen content and lipid peroxidation
Renal function kidney collagen nephridial tissue lipid peroxidation group n serum serum creatinine nephridial tissue nephridial tissue nephridial tissue
BUN (mmol/L) (μ mol/L) Hyp (μ g/g) SOD (NU/ml) MDA normal group 9 6.6 ± 0.3 30.2 ± 16.7 258.7 ± 28.6 275.4 ± 29.6 39.1 ± 4.4 model group 9 15.6 ± 4.4 139.8 ± 14.9 970.9 ± 63.1 220.2 ± 44.8 57.2 ± 21.2 treatments are organized 12 8.6 ± 2.9 106.2 ± 22 793.7 ± 66.7 284.1 ± 68.6 44.8 ± 10.5 nephridial tissue pathologic findings and are found, supporting vital QI and dispersing blood stasis side significantly alleviates rat model nephridial tissue tubule inflammation, alleviate rat model kidney interstitial collagen deposition, Fig. 1, Fig. 2.
The pharmacology brief summary: supporting vital QI and dispersing blood stasis side significantly improves the renal function of renal fibrosis rat, alleviates pipe inflammation necrosis on the kidney, reduces kidney collagenation and deposition, alleviates the nephridial tissue lipid peroxidation.Have good preventing from heavy metal and poison and the kidney region fibrosis effect, one of its main mechanism of action is anti-nephridial tissue peroxidating.
The above results shows that Chinese medicine preparation of the present invention has the new purposes of improving renal fibrosis.
Chinese medicine composition of the present invention can be used for preparing the pharmaceutical preparation that improves fiber.
Description of drawings: 1, Fig. 1-1 nephridial tissue HE dyeing normal group, Fig. 1-2 nephridial tissue PASM collagen staining normal group; 2, Fig. 2-1 nephridial tissue HE dyeing model group, Fig. 2-2 nephridial tissue PASM collagen staining model group; 3, Fig. 3-1 nephridial tissue HE dyeing supporting vital QI and dispersing blood stasis side's treatment group, Fig. 3-2 nephridial tissue PASM collagen staining supporting vital QI and dispersing blood stasis side's treatment group.
Nephridial tissue HE dyeing among the last figure, the degeneration of model group renal tubular cell, a matter inflammatory cell infiltration are clearly better after the treatment of supporting vital QI and dispersing blood stasis side.Nephridial tissue PASM collagen staining, model group renal tubular necrosis, interstitial fibers hypertrophy are clearly better after the treatment of supporting vital QI and dispersing blood stasis side.
The specific embodiment:
Embodiment 1,
The xx of the Qin, the man, 55 years old, the peasant was because of " abdominal discomfort, borborygmus are suffered from diarrhoea day surplus in the of 20 " took in institute, admission number: 457181 on the 20th in December in 2002.In urine have albumen because of foam in the urine increases November calendar year 2001, looks into blood creatinine (SCR) in local hospital: 179 μ mol/l, blood urea nitrogen (BUN): 8.3mmol/l.B ultrasonic shows " right kidney dwindles, in calculus is arranged, skin medullary substance boundary is unclear, the cortex attenuation, echo strengthens, " check urine protein in back adds for half always or is negative.
The edema history is denied history of hypertension when denying the children, denies hepatitis, typhoid fever, and the tuberculosis medical history is denied familial nephropathy medical history, no penicillin anaphylaxis history.Before more than 20 day, abdominal discomfort occurs after taking traditional Chinese medicine, feel sick, borborygmus are promptly suffered from diarrhoea, and are yellow loose stool every day 25 times, do not have sticking freeze bloody purulent stool, no jaundice melena, no tenesmus.
Right kidney percussion pain is suspicious when being admitted to hospital, the left side feminine gender, and it is soft to reach matter under the right rib of liver, does not reach under the spleen rib.The abdominal cavity B ultrasonic: " gallbladder meets chronic inflammatory disease and becomes, and right kidney dwindles, liver, spleen, left kidney no abnormality seen ", Color Sonography was normal, routine blood test, stool routine, a biochemical complete set, urine Bence Jones protein, ANA series, HB
sAG is all negative.Urine β
2-MG:9 μ g/h, blood β
2-MG:5.6mg/lCCR:50ML/ branch, full rabat, breast CT are all shown " calcification of bottom right lung old tuberculosis ".EKG:STT 2,3, V5 to 6 lead low flat ".Intestinal mirror: chronic colitis.
Diagnosis: interstitial nephritis, chronic colitis.
Treatment: supporting vital QI and dispersing blood stasis side (capsule), 5,3 times/day, took continuously 3 months.Colitis gives anti symptom treatment.
Check right kidney percussion pain feminine gender, lather collapse in the urine after March.Urine protein (-) or (±).Urine β
2-MG:4 μ g/h, blood β
2-MG:2.6mg/l, SCR:130 μ mol/l, BUN:6.0mmol/l, B ultrasonic point out right kidney to dwindle.
Embodiment 2
Xu Zhongxing, the man, 64 years old peasant, because of " xerostomia, polydipsia, polyphagia 8 years, dysuria increased the weight of ten days in 5 years " in income institute on October 19th, 2002.Admission number: find that because of heating, xerostomia, polydipsia, polyphagia remove local hospital admission blood sugar increasing is greater than 12mmol/L in October, 457441,95.
Be diagnosed as " type ii diabetes ", long clothes diamicron, metformin, blood glucose is once stable, often occurs urinating because of about about 5 years of difficulty, is diagnosed as prostate hyperplasia, and urine protein second half year calendar year 2001 appears in hypertension in 2000 ++, poor blood glucose control is looked in outpatient service.This is because of dysuria, frequent micturition, and the creatinine of having a blood test raises and income institute.When being admitted to hospital T:37.4 ℃: BP:165 100mmHg; EKG: Dou Su, left ventricular hypertrophy strain, abdominal cavity prostate B ultrasonic: prostatic hyperplasia, the slight hydrops of bilateral kidney, wall of urinary bladder hair; Routine blood test is normal, and is biochemical a complete set of: ALT:44, BUN:9.7mmol/L, SCR:221 μ mol/L, urine β
2-MG:11 μ g/h, blood β
2-MG:7.6mg/L; URIC:501; GLU:14; TCHOL:2.75; NA:153; CL:109; LDH:240 (more than be lift-off value).Be admitted to hospital the back May 25 because of the capable interim urethral catheterization of acute urinary retention once.
Diagnosis is considered: diabetes, diabetic nephropathy, hypertensive nephropathy, interstitial nephritis, chronic kidney hypofunction.
Treatment: supporting vital QI and dispersing blood stasis side (capsule), 5,3 times/day, took continuously 3 months.Hypertension, diabetes give blood pressure lowering, blood sugar lowering anti symptom treatment.
Check urine protein (+).Urine β
2-MG:5.3 μ g/h, blood β
2-MG:3.8mg/l, BUN:6.5mmol/L, SCR:143 μ mol/L, B ultrasonic prompting prostate hyperplasia, two kidneys dwindle slightly, no hydrops.
Claims (4)
1, a kind of Chinese medicine composition improves application in the Chinese medicine preparation of renal fibrosis in preparation, it is characterized in that this Chinese medicine composition comprises following components in portion by weight: Semen Persicae 50-250, Radix Salviae Miltiorrhizae 300-700, Herb Gynostemmae Pentaphylli 200-600, fermented Cordyceps powder 150-450, Pollen Pini 50-250, Fructus Schisandrae Chinensis 50-250, starch are an amount of.
2, a kind of Chinese medicine preparation that is used to improve renal fibrosis according to claim 1 is characterized in that wherein said Chinese medicine composition each component is following weight proportion: Semen Persicae 100-200, Radix Salviae Miltiorrhizae 500-600, Herb Gynostemmae Pentaphylli 300-500, fermented Cordyceps powder 200-300, Pollen Pini 100-200, Fructus Schisandrae Chinensis 100-200, starch are an amount of.
3, a kind of Chinese medicine preparation that is used to improve renal fibrosis according to claim 1 is characterized in that wherein said Chinese medicine composition each component is following weight proportion: Semen Persicae 130, Radix Salviae Miltiorrhizae 530, Herb Gynostemmae Pentaphylli 400, fermented Cordyceps powder 260, Pollen Pini 130, Fructus Schisandrae Chinensis 130, starch are an amount of.
4, a kind of Chinese medicine preparation that is used to improve renal fibrosis according to claim 1 is characterized in that wherein said preparation method is: take by weighing Radix Salviae Miltiorrhizae, Semen Persicae, Herb Gynostemmae Pentaphylli and decoct with water collecting decoction, get supernatant, be condensed into extractum, cooling, add ethanol, precipitation filters; Other takes by weighing fermented Cordyceps powder, and Fructus Schisandrae Chinensis adds alcohol heat reflux, and cooling merges ethanol liquid, filters the filtrate concentrate drying; Other takes by weighing Pollen Pini and adds the ethanol warm macerating, merges leachate, and concentrate drying becomes dried cream, gets above-mentioned three kinds of dried cream, mixes and pulverizes, and it is an amount of to add starch, mixing, and the fill capsule, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03129035 CN1247229C (en) | 2003-06-04 | 2003-06-04 | Chinese medicinal preparation for improving kidney fibrosis and its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03129035 CN1247229C (en) | 2003-06-04 | 2003-06-04 | Chinese medicinal preparation for improving kidney fibrosis and its production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456348A true CN1456348A (en) | 2003-11-19 |
| CN1247229C CN1247229C (en) | 2006-03-29 |
Family
ID=29411713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03129035 Expired - Lifetime CN1247229C (en) | 2003-06-04 | 2003-06-04 | Chinese medicinal preparation for improving kidney fibrosis and its production |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1247229C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899415B (en) * | 2006-01-12 | 2010-05-12 | 上海现代中医药技术发展有限公司 | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method |
| CN104725401A (en) * | 2015-03-05 | 2015-06-24 | 中国科学院昆明植物研究所 | Ganoderma sinense lactam A, and pharmaceutical composition and application thereof in pharmacy and food |
| US9138449B2 (en) | 2006-01-12 | 2015-09-22 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Medicinal composition for liver diseases |
| CN104922238A (en) * | 2015-06-10 | 2015-09-23 | 周耀忠 | Application of traditional Chinese medicine composition in preparation of drugs for treating and preventing renal fibrosis |
| CN105106697A (en) * | 2015-09-07 | 2015-12-02 | 江志鑫 | Pharmaceutical composition for resisting renal fibrosis and application of pharmaceutical composition |
| CN105412117A (en) * | 2015-12-29 | 2016-03-23 | 南京大学 | Composition and application thereof in preparation of drugs for treating or preventing renal fibrosis |
-
2003
- 2003-06-04 CN CN 03129035 patent/CN1247229C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899415B (en) * | 2006-01-12 | 2010-05-12 | 上海现代中医药技术发展有限公司 | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method |
| US9138449B2 (en) | 2006-01-12 | 2015-09-22 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Medicinal composition for liver diseases |
| CN104725401A (en) * | 2015-03-05 | 2015-06-24 | 中国科学院昆明植物研究所 | Ganoderma sinense lactam A, and pharmaceutical composition and application thereof in pharmacy and food |
| CN104725401B (en) * | 2015-03-05 | 2017-01-18 | 中国科学院昆明植物研究所 | Ganoderma sinense lactam A, and pharmaceutical composition and application thereof in pharmacy and food |
| CN104922238A (en) * | 2015-06-10 | 2015-09-23 | 周耀忠 | Application of traditional Chinese medicine composition in preparation of drugs for treating and preventing renal fibrosis |
| CN105106697A (en) * | 2015-09-07 | 2015-12-02 | 江志鑫 | Pharmaceutical composition for resisting renal fibrosis and application of pharmaceutical composition |
| CN105412117A (en) * | 2015-12-29 | 2016-03-23 | 南京大学 | Composition and application thereof in preparation of drugs for treating or preventing renal fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1247229C (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444611B (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN103860699B (en) | A kind of pharmaceutical composition for effecting a radical cure three-hypers | |
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN101524471A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN1247229C (en) | Chinese medicinal preparation for improving kidney fibrosis and its production | |
| CN103623292A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN103316101B (en) | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN103638389A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN100434112C (en) | Pure Chinese medicine for treating hyperplasia of mammary glands and preparing method | |
| CN100998674B (en) | Traditional Chinese medicine composition with functions of lowering blood-fat and reducing weight | |
| CN1772119A (en) | Medicine for treating coronary heart disease and angina pectoris and its prepn | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN101987188B (en) | Biological Chinese patent drug for preventing and treating hyperlipoidemia | |
| CN1557378A (en) | Medicine for treating diabetes | |
| CN100534486C (en) | Chinese medicinal preparation for treating proteinuria caused by diabetic nephropathy and preparation method thereof | |
| Wu et al. | Research progress in the treatment of diabetic kidney disease with Chinese medicine enema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200511 Address after: Room 3301, 33 / F, Zhaofeng Plaza, 1027 Changning Road, Shanghai 200050 Patentee after: Shanghai Sundise Chinese Medicine Technology Development Co.,Ltd. Address before: 200032 No. 530, Lingling Road, Shanghai, Xuhui District Patentee before: Shanghai University of Traditional Chinese Medicine |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060329 |